Literature DB >> 22005785

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.

C Kellner, D Hallack, P Glorius, M Staudinger, S Mohseni Nodehi, M de Weers, J G J van de Winkel, P W H I Parren, M Stauch, T Valerius, R Repp, A Humpe, M Gramatzki, M Peipp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22005785     DOI： 10.1038/leu.2011.288

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

Review 1.  Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.

Authors:  Nicole C Smits; Tiffany A Coupet; Claire Godbersen; Charles L Sentman
Journal:  Expert Opin Biol Ther       Date:  2016-06-09       Impact factor: 4.388

2.  Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Authors:  Christian Kellner; Andreas Günther; Andreas Humpe; Roland Repp; Katja Klausz; Stefanie Derer; Thomas Valerius; Matthias Ritgen; Monika Brüggemann; Jan Gj van de Winkel; Paul Whi Parren; Michael Kneba; Martin Gramatzki; Matthias Peipp
Journal:  Oncoimmunology       Date:  2015-06-05       Impact factor: 8.110

Review 3.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

4.  Tumor immunotherapy: New aspects of natural killer cells.

Authors:  Yangxi Li; Rui Sun
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

Review 5.  Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.

Authors:  Matthias Peipp; Katja Klausz; Ammelie Svea Boje; Tobias Zeller; Stefan Zielonka; Christian Kellner
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

6.  Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients.

Authors:  M Christina Cox; Simone Battella; Raffaella La Scaleia; Sabrina Pelliccia; Arianna Di Napoli; Alessandra Porzia; Francesca Cecere; Eleonora Alma; Alessandra Zingoni; Fabrizio Mainiero; Luigi Ruco; Bruno Monarca; Angela Santoni; Gabriella Palmieri
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

Review 7.  New prospects on the NKG2D/NKG2DL system for oncology.

Authors:  Evelyn Ullrich; Joachim Koch; Adelheid Cerwenka; Alexander Steinle
Journal:  Oncoimmunology       Date:  2013-10-25       Impact factor: 8.110

8.  VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer.

Authors:  Wei Xie; Fang Liu; Youfu Wang; Xueyan Ren; Tong Wang; Zhiguo Chen; Mingying Tang; Fumou Sun; Zhaoting Li; Min Wang; Juan Zhang
Journal:  Oncotarget       Date:  2016-03-29

9.  HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.

Authors:  Matthias Peipp; Stefanie Derer; Stefan Lohse; Matthias Staudinger; Katja Klausz; Thomas Valerius; Martin Gramatzki; Christian Kellner
Journal:  Oncotarget       Date:  2015-10-13

10.  Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype.

Authors:  Christian Kellner; Martin Gramatzki; Matthias Peipp
Journal:  Oncoimmunology       Date:  2013-05-09       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.